Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18373410 | 0.87 | SIGMAR1 (0.54) | SIGMAR1MEN1KMT2AKAT2B | |
| SCHEMBL14653932 | 0.84 | SIGMAR1 (0.55) | SIGMAR1MEN1KMT2AHRH3 | |
| SCHEMBL18373453 | 0.81 | SIGMAR1 (0.54) | SIGMAR1MEN1KMT2AKCNH2 | |
| SCHEMBL18373435 | 0.81 | SIGMAR1 (0.54) | SIGMAR1MEN1KMT2AKCNH2 | |
| SCHEMBL14646799 | 0.81 | SIGMAR1 (0.55) | SIGMAR1MEN1KMT2AHRH3 | |
| SCHEMBL18373478 | 0.79 | SIGMAR1 (0.59) | SIGMAR1KMT2AALDH1A1 | |
| SCHEMBL18373412 | 0.76 | SIGMAR1 (0.43) | SIGMAR1HRH3 | |
| SCHEMBL18373438 | 0.76 | SIGMAR1 (0.41) | SIGMAR1MEN1KMT2AKAT2B | |
| SCHEMBL14646733 | 0.76 | MEN1 (0.45) | SIGMAR1MEN1KMT2AHRH3KAT2B | |
| SCHEMBL18373452 | 0.75 | SIGMAR1 (0.59) | SIGMAR1MEN1KMT2AKCNH2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2734524-B1 | PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS, THEIR PREPARATION AND USE AS SIGMA LIGANDS | ESTEVE LABOR DR (ES) | 2017-01-11 | — | — | EP | disclosed |
| US-20150315190-A2 | PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS, THEIR PREPARATION AND USE AS SIGMA LIGANDS | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2015-11-05 | — | — | US | disclosed |
| US-20150315190-A2 | PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS, THEIR PREPARATION AND USE AS SIGMA LIGANDS | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2015-11-05 | — | — | US | disclosed |
| WO-2013010950-A1 | PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS, THEIR PREPARATION AND USE AS SIGMA LIGANDS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2013-01-24 | — | — | WO | disclosed |
| EP-2548878-A1 | Pyrazolo[3,4-d]pyrimidine compounds, their preparation and use as sigma ligands | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2013-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150315190-A2 | PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS, THEIR PREPARATION AND USE AS SIGMA LIGANDS | SIGMAR1, P2RX4, P2RX3 | SIGMAR1 1/4885MEN1 4752/4885KMT2A 4379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.